Welcome to our dedicated page for Mei Pharma SEC filings (Ticker: MEIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MEIP SEC filings page on Stock Titan aggregates U.S. Securities and Exchange Commission documents for MEI Pharma, Inc., including key 8-K current reports that explain its corporate evolution and strategic decisions. These filings provide primary-source detail on both the company’s historical role as a clinical-stage oncology business and its later transition toward a Litecoin-focused digital asset treasury strategy under the Lite Strategy, Inc. name.
Among the most significant filings is an 8-K dated September 10, 2025, in which the company reports an amendment to its certificate of incorporation changing its name to Lite Strategy, Inc. and notes that its common stock will cease trading under the MEIP ticker and begin trading under LITS on the NASDAQ Capital Market. Other 8-Ks describe the private placement used to fund the Litecoin treasury initiative, the subsequent acquisition of Litecoin tokens, and governance developments such as board changes and the appointment of GSR as asset manager for the company’s digital asset treasury.
Additional filings outline material agreements and financial obligations tied to the digital asset strategy, including a master loan agreement with BitGo Prime, LLC that establishes a framework for borrowing digital assets or cash secured by collateral. Earlier filings and related disclosures also reflect the company’s strategic alternatives process, workforce reductions, and changes in its clinical development activities.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the core points of each document, helping users quickly understand amendments to corporate structure, financing terms, treasury arrangements, and other material events. Investors can use this page to locate historical MEIP filings and to trace how the company’s regulatory record supports its rebranding and ticker change to LITS, while also accessing real-time updates as new Lite Strategy, Inc. filings are released.
Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of Lite Strategy, Inc. common stock on an amended Schedule 13G. Griffin may be deemed to beneficially own 1,433,211 Shares, representing 3.9% of the outstanding common stock.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 1,085,626 Shares, or 3.0% of the class. Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC may each be deemed to beneficially own 347,585 Shares, or 0.9% of the class.
The ownership percentages are based on 36,769,677 Shares outstanding as of December 15, 2025. The reporting group certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Lite Strategy.
Lite Strategy, Inc. reported fiscal 2026 second quarter results centered on a new, more active use of its Litecoin treasury and capital return strategy. The company began transforming its LTC holdings into a “productive reserve asset” by launching a covered call options program that generated nearly $600,000 in gross premiums in the quarter.
Management also used proceeds from these treasury operations to commence a $25 million stock repurchase program, aiming to practice disciplined capital allocation and address the discount to net asset value. As of December 31, 2025, Lite Strategy held $8.8 million in cash and cash equivalents and initiated pre-clinical R&D work on its drug candidate pipeline for potential out-licensing or sale opportunities.
Lite Strategy, Inc. reported a sharp increase in scale and a major shift in strategy for the quarter ended December 31, 2025. Total assets rose to
The company recorded a quarterly net loss of
Lite Strategy, Inc. reported that CEO, CFO and Secretary Justin J. File acquired a stock option covering 455,000 shares of common stock at an exercise price of $2.02 per share on February 12, 2026, as employment compensation.
The option grant was approved by the board on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan, which shareholders approved on February 12, 2026. After this grant, File directly holds 635,000 derivative securities.
The option is 5.6% vested and exercisable as of February 12, 2026, with the remaining 94.4% vesting in 34 monthly installments beginning February 14, 2026, contingent on continued service.
Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.
Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.
At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.
Alexander Schornstein filed a Form 3 disclosing initial beneficial ownership in Lite Strategy, Inc. (MEIP). The filing reports ownership of 4,365,472 shares of Common Stock, of which 4,140,472 are held directly by Mr. Schornstein and 225,000 are held by Camino Capital GmbH, an entity of which he is the sole beneficial owner and holds sole voting power.
The filing indicates a reporting relationship to the issuer as a director and was dated as the event on 09/09/2025 with a signature dated 09/10/2025. No derivative securities or exercise terms were reported.
Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock, representing 13.29% of the outstanding class. This holding includes 4,140,472 shares directly held by Mr. Schornstein and 225,000 shares held by Camino Capital GmbH, of which he is the sole beneficial owner with sole voting and dispositive power. The filing states these shares were purchased from August 11, 2025 through September 9, 2025 using the Reporting Person's personal funds and that ownership exceeded the 10% threshold on September 9, 2025.
The filer certifies the securities were not acquired to influence control of the issuer and is filing under the short-form Schedule 13G provision. The percentage is calculated using 32,837,743 shares outstanding as disclosed in the companys Form S-3 Amendment No. 1 dated August 26, 2025. The filing identifies the issuers principal executive office in San Diego, CA and provides the Reporting Persons address in Aachen, Germany.
MEI Pharma, Inc. has changed its corporate name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its certificate of incorporation filed in Delaware. Under Delaware law, this name change did not require a stockholder vote and does not alter the rights of existing stockholders.
Beginning September 11, 2025, the company’s common stock, par value $0.00000002 per share, will stop trading on the Nasdaq Capital Market under the ticker symbol “MEIP” and will start trading under the new ticker symbol “LITS.” The company also issued a news release on September 10, 2025, to announce the new name and ticker.
MEI Pharma, Inc. entered a master loan agreement with BitGo Prime, LLC on
Borrowings under the agreement are secured by collateral that is typically required to exceed the borrowed amount and are subject to margin calls; failure to maintain collateral can lead to default remedies including collateral liquidation. The agreement also includes customary representations, covenants, and events of default. A copy of the master agreement is filed as Exhibit 10.1.
MEI Pharma, Inc. (Nasdaq: MEIP) filed an amended shelf registration on Form S-3/A describing resale of registered shares by selling stockholders and certain warrant terms. The prospectus states 32,837,743 shares of common stock outstanding as of August 25, 2025, assuming full exercise of several warrant series. The company discloses potential gross proceeds if warrants are exercised: approximately $394 from the Pre-Funded Warrants in full, $6.0 million from Asset Manager Warrants, $1.8 million from Strategic Advisor Warrants, and $4.8 million from Placement Agent Warrants, and states any proceeds received would be used to purchase Litecoin.
The filing details transfer agent information (Computershare), indemnification provisions for directors and officers under Delaware law, and risks including cybersecurity threats to digital assets and custody-related losses. It describes the Pre-Funded Warrant mechanics (initial exercise price $0.0001, exercisability, cashless exercise, ownership limits), resale methods for selling stockholders, and incorporation by reference of prior SEC reports and audited financial statements.